Zhu Yi, Zhang Hongtao, Zhang Guonan, Shi Yu, Huang Jianming
Department of Gynaecologic Oncology, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
Department of Ultrasound, Sichuan Cancer Hospital & Institute, Cancer Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
Ann Transl Med. 2019 Mar;7(5):91. doi: 10.21037/atm.2019.01.28.
Cluster of differentiation 44 (CD44)/myeloid differentiation factor 88 (MyD88) is the molecular characterization of EOC stem cells. An important characteristic of CD44+/MyD88+ epithelial ovarian cancer (EOC) cells, which differentiate them from the CD44-/MyD88- EOC cells, is the presence of a functional TLR4-MyD88-NFkB pathway. The aim of our study is to investigate the clinical significance of CD44/MyD88 co-expression in EOC.
A total of 138 specimens of ovarian tissues was detected CD44 and MyD88 expression by immunocytochemistry, including EOC (N=108), borderline tumors (N=10), benign cysts (N=10) and normal ovarian tissue (N=10). The association of CD44/MyD88 co-expression with clinicopathological factors and outcomes was analyzed.
The expression of CD44 was showed distinct difference in EOC (53 of 108, 49.1%), in borderline tumors (3 of 10, 30.0%), in benign cysts (2 of 10, 20.0%) and normal ovarian (2 of 10, 20.0%). A total of 41 (38.0%) cancers showed a combined expression of CD44/MyD88. The expression of CD44 and MyD88 had definitely correlativity (r=0.21, P=0.026). CD44/MyD88 co-expression was associated with tumor progression, metastasis, and recurrence in advanced EOC, and an independent prognostic factor for disease-free survival and overall survival.
CD44/MyD88 co-expression has been shown to contribute to EOC progression and outcome directly and has a promising as a therapeutic target in EOC.
分化簇44（CD44）/髓样分化因子88（MyD88）是上皮性卵巢癌（EOC）干细胞的分子特征。CD44+/MyD88+上皮性卵巢癌细胞与CD44-/MyD88- EOC细胞的一个重要区别在于存在功能性的Toll样受体4（TLR4）-MyD88-核因子κB（NFκB）信号通路。本研究旨在探讨CD44/MyD88共表达在上皮性卵巢癌中的临床意义。
采用免疫细胞化学法检测138例卵巢组织标本中CD44和MyD88的表达，其中包括上皮性卵巢癌（n = 108）、交界性肿瘤（n = 10）、良性囊肿（n = 10）和正常卵巢组织（n = 10）。分析CD44/MyD88共表达与临床病理因素及预后的关系。
CD44的表达在上皮性卵巢癌（108例中的53例，49.1%）、交界性肿瘤（10例中的3例，30.0%）、良性囊肿（10例中的2例，20.0%）和正常卵巢组织（10例中的2例，20.0%）中显示出明显差异。共有41例（38.0%）癌症显示CD44/MyD88联合表达。CD44和MyD88的表达具有显著相关性（r = 0.21，P = 0.026）。CD44/MyD88共表达与晚期上皮性卵巢癌的肿瘤进展、转移和复发相关，是无病生存期和总生存期的独立预后因素。
CD44/MyD88共表达已被证明直接促进上皮性卵巢癌的进展并影响预后，有望成为上皮性卵巢癌的治疗靶点。
